World health organization group 5 pulmonary hypertension

Tim Lahm, Murali M. Chakinala

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

World Health Organization (WHO) group 5 pulmonary hypertension (PH) entails a heterogeneous group of disorders that may cause PH by unclear and/or multiple mechanisms. In particular, group 5 includes PH caused by hematologic disorders, systemic diseases, metabolic disorders, chronic renal failure, and disorders leading to pulmonary vascular occlusion or compression. This article discusses common pathogenic mechanisms leading to group 5 PH, followed by a detailed overview of epidemiology, pathogenesis, and disease-specific management of the individual group 5 conditions. Off-label use of vasomodulatory therapies, typically indicated for pulmonary arterial hypertension (WHO group 1PH), in group 5 conditions is also discussed.

Original languageEnglish
Pages (from-to)753-778
Number of pages26
JournalClinics in Chest Medicine
Volume34
Issue number4
DOIs
StatePublished - Dec 2013

Fingerprint

Pulmonary Hypertension
Off-Label Use
Metabolic Diseases
Disease Management
Chronic Kidney Failure
Blood Vessels
Epidemiology
Lung
Therapeutics

Keywords

  • Fibrosing mediastinitis
  • Lymphangioleiomyomatosis
  • Metabolic disorders
  • Myeloproliferative disorders
  • Pulmonary Langerhans cell histiocytosis
  • Renal failure
  • Sarcoidosis
  • Splenectomy

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

World health organization group 5 pulmonary hypertension. / Lahm, Tim; Chakinala, Murali M.

In: Clinics in Chest Medicine, Vol. 34, No. 4, 12.2013, p. 753-778.

Research output: Contribution to journalArticle

Lahm, Tim ; Chakinala, Murali M. / World health organization group 5 pulmonary hypertension. In: Clinics in Chest Medicine. 2013 ; Vol. 34, No. 4. pp. 753-778.
@article{fab96b5011704857a158996ba16fbb1f,
title = "World health organization group 5 pulmonary hypertension",
abstract = "World Health Organization (WHO) group 5 pulmonary hypertension (PH) entails a heterogeneous group of disorders that may cause PH by unclear and/or multiple mechanisms. In particular, group 5 includes PH caused by hematologic disorders, systemic diseases, metabolic disorders, chronic renal failure, and disorders leading to pulmonary vascular occlusion or compression. This article discusses common pathogenic mechanisms leading to group 5 PH, followed by a detailed overview of epidemiology, pathogenesis, and disease-specific management of the individual group 5 conditions. Off-label use of vasomodulatory therapies, typically indicated for pulmonary arterial hypertension (WHO group 1PH), in group 5 conditions is also discussed.",
keywords = "Fibrosing mediastinitis, Lymphangioleiomyomatosis, Metabolic disorders, Myeloproliferative disorders, Pulmonary Langerhans cell histiocytosis, Renal failure, Sarcoidosis, Splenectomy",
author = "Tim Lahm and Chakinala, {Murali M.}",
year = "2013",
month = "12",
doi = "10.1016/j.ccm.2013.08.005",
language = "English",
volume = "34",
pages = "753--778",
journal = "Clinics in Chest Medicine",
issn = "0272-5231",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - World health organization group 5 pulmonary hypertension

AU - Lahm, Tim

AU - Chakinala, Murali M.

PY - 2013/12

Y1 - 2013/12

N2 - World Health Organization (WHO) group 5 pulmonary hypertension (PH) entails a heterogeneous group of disorders that may cause PH by unclear and/or multiple mechanisms. In particular, group 5 includes PH caused by hematologic disorders, systemic diseases, metabolic disorders, chronic renal failure, and disorders leading to pulmonary vascular occlusion or compression. This article discusses common pathogenic mechanisms leading to group 5 PH, followed by a detailed overview of epidemiology, pathogenesis, and disease-specific management of the individual group 5 conditions. Off-label use of vasomodulatory therapies, typically indicated for pulmonary arterial hypertension (WHO group 1PH), in group 5 conditions is also discussed.

AB - World Health Organization (WHO) group 5 pulmonary hypertension (PH) entails a heterogeneous group of disorders that may cause PH by unclear and/or multiple mechanisms. In particular, group 5 includes PH caused by hematologic disorders, systemic diseases, metabolic disorders, chronic renal failure, and disorders leading to pulmonary vascular occlusion or compression. This article discusses common pathogenic mechanisms leading to group 5 PH, followed by a detailed overview of epidemiology, pathogenesis, and disease-specific management of the individual group 5 conditions. Off-label use of vasomodulatory therapies, typically indicated for pulmonary arterial hypertension (WHO group 1PH), in group 5 conditions is also discussed.

KW - Fibrosing mediastinitis

KW - Lymphangioleiomyomatosis

KW - Metabolic disorders

KW - Myeloproliferative disorders

KW - Pulmonary Langerhans cell histiocytosis

KW - Renal failure

KW - Sarcoidosis

KW - Splenectomy

UR - http://www.scopus.com/inward/record.url?scp=84888197213&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888197213&partnerID=8YFLogxK

U2 - 10.1016/j.ccm.2013.08.005

DO - 10.1016/j.ccm.2013.08.005

M3 - Article

C2 - 24267303

AN - SCOPUS:84888197213

VL - 34

SP - 753

EP - 778

JO - Clinics in Chest Medicine

JF - Clinics in Chest Medicine

SN - 0272-5231

IS - 4

ER -